EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Placental Gene Therapy for Fetal Growth Restriction and Preeclampsia: Preclinical Studies and Prospects for Clinical Application

Sanjukta Majumder iD, Kristen Lee Moriarty iD, Youngmok Lee iD, Timothy M Crombleholme

Journal of Clinical Medicine · 23.09.2024 · 13 (18) · 5647

DOI: 10.3390/jcm13185647 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.09.2024. Verfasst von Sanjukta Majumder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Fetal Therapy Laboratory, Fetal Care Center at Connecticut Children's Medical Center, Suite F254, 282 Washington Street, Hartford, CT 06106…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last three decades, gene therapy has demonstrated significant progress. Over 700 active investigational new drug (IND) applications have been reported. Research on in utero gene therapy has advanced, but ethical and safety concerns persist. A novel approach under investigation is placental gene therapy, which holds promise for targeting diseases associated with placental dysfunction, such as fetal growth restriction (FGR) and preeclampsia. One of the underlying causes of placental insufficiency in these conditions is reduced placental growth factor-driven angiogenesis and endothelial cell dysfunction during fetal development. Studies have explored the overexpression of growth factor transgenes like IGF-1 to address FGR, yielding promising outcomes in animal models. Furthermore, intra-placental gene transfer, instead of systemic delivery of gene therapy vectors, has the potential to treat and cure these disorders. However, challenges and limitations akin to in utero gene therapy persist, including the risk of in utero infection, potential impairment of the mother’s future fertility, the risk of germline integration, and possible off-target effects of gene transfer in the fetus or the mother. Consequently, additional research and deliberation within the scientific and medical communities are warranted to fully comprehend the potential benefits and risks of placental gene therapy.

Schlagwörter

Stichwörter der Autor:innen

IGF-1fetal growth restrictiongene therapyplacentapreeclampsia

Autor:innen und Institutionen

  • Molecular Fetal Therapy Laboratory, Fetal Care Center at Connecticut Children's Medical Center, Suite F254, 282 Washington Street, Hartford, CT 06106, USA.
  • Fetal Surgery Section, Division of Pediatric General and Thoracic Surgery, Department of Surgery, UConn Health, Farmington, CT 06030, USA.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Farmington, CT 06030, USA.
  • Department of Pediatrics, School of Medicine, University of Connecticut, Farmington, CT 06030, USA.

ORCID-Profile: Sanjukta Majumder, Kristen Lee Moriarty, Youngmok Lee

Zitieren

APA

Majumder, S., Moriarty, K. L., Lee, Y., & Crombleholme, T. M. (2024). Placental Gene Therapy for Fetal Growth Restriction and Preeclampsia: Preclinical Studies and Prospects for Clinical Application. Journal of Clinical Medicine, 13(18), 5647. https://doi.org/10.3390/jcm13185647

Vancouver

Majumder S, Moriarty KL, Lee Y, Crombleholme TM. Placental Gene Therapy for Fetal Growth Restriction and Preeclampsia: Preclinical Studies and Prospects for Clinical Application. Journal of Clinical Medicine. 2024;13(18):5647. doi:10.3390/jcm13185647

BibTeX
@article{Majumder2024,
  author = {Majumder, Sanjukta and Moriarty, Kristen Lee and Lee, Youngmok and Crombleholme, Timothy M},
  title = {Placental Gene Therapy for Fetal Growth Restriction and Preeclampsia: Preclinical Studies and Prospects for Clinical Application},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {18},
  pages = {5647},
  doi = {10.3390/jcm13185647}
}
Kostenlos starten →